ライフサイエンスコーパス: adjusted hazard ratio

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 8%) of 207 in the active surveillance group (adjusted hazard ratio 0.34, 95% CI 0.24-0.46; p<0.0001).

2 100 person-yrs in the no-intervention group, adjusted hazard ratio 0.55 (95% CI, 0.34-0.91; P = 0.019

3 duction in colorectal cancer incidence rate (adjusted hazard ratio 0.57, 95% CI 0.40-0.80 for one vis

4 23 months (5.52-not estimable) with placebo (adjusted hazard ratio 0.81, 95% CI 0.55-1.21; log-rank p

5 edian disease-free survival was not reached (adjusted hazard ratio 0.97 [95% CI 0.86-1.10], p=0.64).

6 antly higher graft failure risks than males (adjusted hazard ratios 0-14 years: 1.51 [95% confidence

7 ted and nonsignificant in adjusted analysis (adjusted hazard ratio = 0.77, 95% confidence interval =

8 y confounders indicated no increase in risk (adjusted hazard ratio = 0.83, 95% confidence interval: 0

9 sociated with tSCC in multivariate analysis (adjusted hazard ratio = 0.83; 95% confidence interval [C

10 ist compared with those aged 18 to 24 years (adjusted hazard ratio, 0-5 years = 0.36; 6-11 = 0.29; 12

11 en with the rs7216389 high-risk TT genotype (adjusted hazard ratio, 0.16; 95% CI, 0.04-0.71; P = .015

12 VAC rescue (median, 36 minutes after injury; adjusted hazard ratio, 0.17 [95% CI, 0.04 to 0.73], P =

13 risk of mumps than receipt of a second dose (adjusted hazard ratio, 0.22; 95% confidence interval, 0.

14 k of HCC (0.90 vs 3.45 HCC/100 person-years; adjusted hazard ratio, 0.28, 95% CI=0.22-0.36).

15 with an earlier-generation fluoroquinolone (adjusted hazard ratio, 0.46 [95% confidence interval, .2

16 1.73 m(2)) and lower risk of graft failure (adjusted hazard ratio, 0.50 [95% CI, 0.27 to 0.94]).

17 outcomes in a step-wise graded relationship (adjusted hazard ratio, 0.60; 95% confidence interval, 0.

18 ard ratio, 0.65; 95% CI, 0.61-0.70; females: adjusted hazard ratio, 0.64; 95% CI, 0.58-0.70).

19 after eligibility was 35% lower (for males: adjusted hazard ratio, 0.65; 95% CI, 0.61-0.70; females:

20 % reduction in rate of progression or death (adjusted hazard ratio, 0.66; 95% CI, 0.46 to 0.95; one-s

21 d postoperative organ dysfunction by day 30 (adjusted hazard ratio, 0.66; 95% CI, 0.52 to 0.84; P = .

22 ificantly lower risk of long-term mortality (adjusted hazard ratio, 0.70; 95% CI, 0.59-0.84; P < .001

23 ed across the years of transplant (2006-2009 adjusted hazard ratio, 0.70; P = 0.009; referent 1994-19

24 reduction in the hazard of death after LVAD (adjusted hazard ratio, 0.73; 95% confidence interval, 0.

25 ce infection at 5 years relative to capping (adjusted hazard ratio, 0.78; 95% CI, 0.62-0.97; P=0.027)

26 reduction in the hazard of death after LVAD (adjusted hazard ratio, 0.78; 95% confidence interval, 0.

27 n LDL-C level less than 30 mg/dL at 1 month (adjusted hazard ratio, 0.79; 95% CI, 0.69-0.91; P = .001

28 interval, 0.9 to 4.1; P = 0.1) and patient (adjusted hazard ratio, 0.7; 95% confidence interval, 0.2

29 for every 3-year increase in calendar-time (adjusted hazard ratio, 0.8 [95% CI, .8-.9]) in the multi

30 evelopment in children with the TT genotype (adjusted hazard ratio, 0.83; 95% CI, 0.71-0.97; P = .022

31 therapy, NAT patients had a better survival (adjusted hazard ratio, 0.83; 95% CI, 0.73 to 0.89).

32 ctive for time to death among UNOS status 2 (adjusted hazard ratio, 0.85; 95% confidence interval, 0.

33 combination therapy (median, 55 vs 59 hours; adjusted hazard ratio, 0.87; 95% CI, 0.74-1.01).

34 ther the presence of circulating antibodies (adjusted hazard ratio, 0.87; 95% confidence interval, 0.

35 imilar mortality rates compared with whites (adjusted hazard ratio, 0.92; 95% CI, 0.76-1.11 and adjus

36 ed hazard ratio, 0.92; 95% CI, 0.76-1.11 and adjusted hazard ratio, 0.92; 95% CI, 0.76-1.12, respecti

37 onfidence interval, 0.72-1.58) or mortality (adjusted hazard ratio, 0.92; 95% confidence interval, 0.

38 hazard ratio, 1.48; P=0.005) but not in men (adjusted hazard ratio, 0.98, P=0.806).

39 , 1.42-3.59; P=0.0006), but not of bleeding (adjusted hazard ratio, 0.99; 95% confidence interval, 0.

40 ention group and 31.0% in the control group (adjusted hazard ratio, 0.9; 95% CI, 0.6 to 1.2; P=0.46).

41 on had a significantly lower mortality rate (Adjusted hazard ratio: 0.56, 95% CI: 0.40-0.79), but sig

42 ions annually; and improved 1-year survival (adjusted hazard ratio: 0.95 for every additional 10 oper

43 rson-years (2.00-2.54) in the control group (adjusted hazard ratio 1.01, 95% CI 0.87-1.17; p=0.89).

44 unction but not all-cause allograft failure (adjusted hazard ratio 1.01, 95% CI 0.96-1.07).

45 te between observed BMI and AF (age- and sex-adjusted hazard ratio 1.05 [1.04-1.06] per kg/m(2), P<0.

46 he control group (median 48 days vs 62 days, adjusted hazard ratio 1.78; 95% CI 1.22-2.58, p=0.003),

47 .6 [26.1-27.2] events per 1000 person-years, adjusted hazard ratio 1.91 [95% CI 1.63-2.25]; adjusted

48 associated with past smoking (multivariable-adjusted hazard ratio = 1.09, 95% confidence interval: 1

49 antly associated with T2D risk (multivariate-adjusted hazard ratio = 1.13, 95% CI: 1.01, 1.25; P for

50 adjustment for red meat intake (multivariate-adjusted hazard ratio = 1.14, 95% CI: 1.02, 1.28; P for

51 r mortality than those without missing data (adjusted hazard ratio = 1.36, 95% confidence interval: 1

52 ations compared with the general population (adjusted hazard ratio = 1.45; 95% confidence interval =

53 42-1.49) and their unaffected full siblings (adjusted hazard ratio = 1.47; 95% confidence interval =

54 iation was attenuated in mediation analyses (adjusted hazards ratio = 1.25, 95% confidence interval:

55 v 4.4 per 1,000 person-years, respectively; adjusted hazard ratio, 1.02; 95% CI, 0.87 to 1.19).

56 for maximal MBF and clinical covariates; and adjusted hazard ratio, 1.03; 95% CI, 0.84-1.27; P=0.8 pe

57 men with pregnancy before breast cancer (age-adjusted hazard ratio, 1.03; 95% CI, 0.85-1.27; P = .73)

58 we found that maternal influenza infection (adjusted hazard ratio, 1.04; 95% CI, 0.68-1.58) or influ

59 I, 1.09-1.85) without a change in mortality (adjusted hazard ratio, 1.05; 95% CI, 0.93-1.19).

60 significantly influence the risk of stroke (adjusted hazard ratio, 1.07; 95% confidence interval, 0.

61 hout psoriatic arthritis was not identified (adjusted hazard ratio, 1.09; 95% CI, 1.00-1.20).

62 e time to sputum culture conversion overall (adjusted hazard ratio, 1.09; 95% confidence interval, 0.

63 er hour increase in the total ischemic time (adjusted hazard ratio, 1.09; 95% confidence interval, 1.

64 95% CI, 0.68-1.58) or influenza vaccination (adjusted hazard ratio, 1.10; 95% CI, 1.00-1.21) anytime

65 days (IQR, 3-10 days) in the placebo group (adjusted hazard ratio, 1.11; 95% CI, 0.89-1.39; P = .36

66 s that were not different (6.1% versus 6.7%; adjusted hazard ratio, 1.12; 95% confidence interval, 0.

67 nificant risk of death among UNOS status 1A (adjusted hazard ratio, 1.14; 95% confidence interval, 1.

68 gher incidence of death (16.8% versus 14.4%; adjusted hazard ratio, 1.14; P=0.01), readmission (45.5%

69 nce interval, 1.01-1.29) and UNOS status 1B (adjusted hazard ratio, 1.17; 95% confidence interval, 1.

70 with pregnancy-associated breast cancer (age-adjusted hazard ratio, 1.18; 95% CI, 0.91-1.53; P = .20)

71 ugmented the risk of acute rejection by 20% (adjusted hazard ratio, 1.20, 1.13-1.28; P < 0.001) and t

72 ed, but the association was not significant (adjusted hazard ratio, 1.20; 95% CI, 0.82 to 1.74).

73 y period associated with increased ASD risk (adjusted hazard ratio, 1.20; 95% CI, 1.04-1.39).

74 time in the late-parenteral-nutrition group (adjusted hazard ratio, 1.23; 95% CI, 1.11 to 1.37).

75 < 0.001) and the risk of graft loss by 30% (adjusted hazard ratio, 1.30, 1.23-1.37; P < 0.001), with

76 atio, 1.43; 95% CI, 1.03-1.98) and Medicaid (adjusted hazard ratio, 1.30; 95% CI, 1.10-1.52).

77 iable (P = .019) and multivariable analyses (adjusted hazard ratio, 1.31; 95% CI, 1.00 to 1.72 for GG

78 was associated with higher risk of dementia (adjusted hazard ratio, 1.31; 95% confidence interval per

79 However, the risk of hospitalization (adjusted hazard ratio, 1.34; 95% confidence interval, 1.

80 ents than those who continued (multivariable-adjusted hazard ratio, 1.37; 95% confidence interval, 1.

81 o had an increased risk of incident uveitis (adjusted hazard ratio, 1.42; 95% CI, 1.23-1.64; and 1.42

82 were observed for those with Medicare only (adjusted hazard ratio, 1.43; 95% CI, 1.03-1.98) and Medi

83 the risk for the composite outcome in women (adjusted hazard ratio, 1.48; P=0.005) but not in men (ad

84 nfidence interval, 1.39-1.70) and mortality (adjusted hazard ratio, 1.50; 95% confidence interval, 1.

85 ing long-term opioids, including depression (adjusted hazard ratio, 1.53; 95% CI, 1.29-1.82), opioid

86 d with an increased risk of hospitalization (adjusted hazard ratio, 1.54; 95% confidence interval, 1.

87 nterval, 0.50-1.54) nor the presence of DSA (adjusted hazard ratio, 1.56; 95% confidence interval, 0.

88 nts with and without diabetes mellitus died (adjusted hazard ratio, 1.59; confidence interval, 1.33-1

89 d risk of developing MH compared with males (adjusted hazard ratio, 1.64; 95% CI, 1.11-2.43; P = .01)

90 adjustment for important baseline variables (adjusted hazard ratio, 1.68; 95% confidence interval, 1.

91 rsus 22% of those without diabetes mellitus (adjusted hazard ratio, 1.75; 95% confidence interval, 1.

92 with prefatherhood paternal areca nutusage (adjusted hazard ratio, 1.77; 95% confidence interval [CI

93 events than men with nonobstructive LM CAD (adjusted hazard ratio, 1.78; P=0.017); sex-specific inte

94 gent used, and revascularization after scan (adjusted hazard ratio, 1.79; 95% confidence interval [CI

95 after propensity-score matching (propensity-adjusted hazard ratio, 1.79; 95% confidence interval, 1.

96 reduced in patients with LLH on sildenafil (adjusted hazard ratio, 1.7; 95% confidence interval, 0.2

97 emia-driven target vessel revascularization (adjusted hazard ratio, 1.82; 95% confidence interval, 1.

98 strongly predicted risk for subsequent MACE (adjusted hazard ratio, 1.90; 95% confidence interval, 1.

99 .001) or persistently so (22.5% versus 8.8%; adjusted hazard ratio, 1.90; 95% confidence interval, 1.

100 ients without depression (10.8% versus 6.1%; adjusted hazard ratio, 1.91; 95% confidence interval, 1.

101 erhood (Ptrend=0.0002), with increased risk (adjusted hazard ratio, 1.95; 95% CI, 1.26-3.04) for pate

102 reased among participants with a score of 1 (adjusted hazard ratio, 1.9; 95% CI, 1.4-2.6), 2 (hazard

103 Post-KT graft (adjusted hazard ratio, 1.9; 95% confidence interval, 0.9

104 uent when recipients or donors had iciHHV-6 (adjusted hazard ratios, 1.7-1.9; P = .004-.001).

105 years of age, versus from >30 years of age (adjusted hazard ratio,1.61; 95% CI, 0.22-11.69).

106 mortality compared with Vmax 4 to 4.49 m/s (adjusted hazard ratio=1.34 [1.18-1.52]; P<0.001, and 1.2

107 th Vmax >/=5 m/s had greater mortality risk (adjusted hazard ratio=1.86 [1.55-2.54]; P<0.001), even i

108 zed (unadjusted, 12.1% versus 2.4%, P<0.001; adjusted hazard ratio, 10.6, 95% CI, 7.7-14.8) and nonre

109 h NSVT runs at a rate >200 beats per minute (adjusted hazard ratio, 15.63; 95% confidence interval, 4

110 ssociated with a greater risk of thrombosis (adjusted hazard ratio, 15; 95% confidence interval, 4.5-

111 .001) and with death or heart failure (n=50, adjusted hazard ratio, 16.0 [2.04-126], P<0.001).

112 ssion model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31

113 aging findings, and early revascularization (adjusted hazard ratio, 2.05; 95% confidence interval, 1.

114 01-4.36; P<0.001), and cardiovascular death (adjusted hazard ratio, 2.16; 95% confidence interval, 1.

115 with normal renal function (24% versus 10%; adjusted hazard ratio, 2.19; 95% CI, 1.54-3.11).

116 ty, geographic location, and marital status (adjusted hazard ratio, 2.19; 95% CI, 1.84 to 2.60).

117 1.37-2.42; P<0.0001), and stent thrombosis (adjusted hazard ratio, 2.26; 95% confidence interval, 1.

118 2-year risk of major adverse cardiac events (adjusted hazard ratio, 2.34; 95% confidence interval, 1.

119 ith an increased rate of ILD-specific death (adjusted hazard ratio, 2.3; 95% confidence interval, 1.7

120 tis compared with the nonpsoriatic controls (adjusted hazard ratio, 2.40; 95% CI, 1.90-3.02).

121 th an increased rate of ILD hospitalization (adjusted hazard ratio, 2.6 per 1-SD increment in high-at

122 hsTnI was newly elevated (28.1% versus 8.8%; adjusted hazard ratio, 2.65; 95% confidence interval, 1.

123 had a 177% increased risk of developing MH (adjusted hazard ratio, 2.77; 95% CI, 1.27-6.02; P = .01)

124 1.53; 95% CI, 1.29-1.82), opioid dependence (adjusted hazard ratio, 2.85; 95% CI, 1.54-5.47), and opi

125 ons was associated with earlier readmission (adjusted hazard ratio, 2.9 for one complex chronic condi

126 erval, 1.46-2.48; P<0.001), all-cause death (adjusted hazard ratio, 2.96; 95% confidence interval, 2.

127 rofile (10-year cumulative incidence, 4.83%; adjusted-hazard ratio, 2.32; 95% CI, 1.18-4.54).

128 azards model with time-dependent covariates (adjusted hazard ratio: 2.43 [1.49-3.95], P = .0038 and 4

129 en in the subgroup of asymptomatic patients (adjusted hazard ratio=2.08 [1.25-3.46]; P=0.005).

130 exposure to voriconazole and other azole(s) (adjusted hazard ratio 3.45, 95% confidence interval 1.07

131 uicide than those without (0.54% vs. 0.14%): adjusted hazards ratio = 3.76, 95% confidence interval:

132 with either first-generation antipsychotics (adjusted hazard ratio, 3.06; 95% CI, 1.32-7.05) or secon

133 associated with a 3-fold risk for type 2 DM (adjusted hazard ratio, 3.07 [CI, 2.88 to 3.27]; P < 0.00

134 [CI], 1.23-2.53) versus nonchewing fathers (adjusted hazard ratio, 3.28; 95% CI, 1.67-6.43) with >10

135 2-7.05) or second-generation antipsychotics (adjusted hazard ratio, 3.44; 95% CI, 1.73-6.83) increase

136 sychotic treatment was significantly higher (adjusted hazard ratio, 3.64; 95% CI, 1.95-6.82) than the

137 ificantly associated with ICD-treated VT/VF (adjusted hazard ratio, 3.98; 95% confidence interval, 1.

138 person-years in patients without cirrhosis; adjusted hazard ratio, 4.73.

139 85; 95% CI, 1.54-5.47), and opioid overdose (adjusted hazard ratio, 5.12; 95% CI, 1.63-19.62).

140 nT (>/=8.81 ng/L versus <limit of detection; adjusted hazards ratio, 5.59; 95% CI, 2.97-10.68).

141 rs, significantly increased the risk of HCC (adjusted-hazard ratio, 5.06; 95% CI, 2.23-11.47) and 10-

142 zed (unadjusted, 10.0% versus 1.7%, P<0.001; adjusted hazard ratio, 6.1, 95% CI, 4.1-9.2) patients.

143 nterval, 4.01-60.89; P<0.0001) and >7 beats (adjusted hazard ratio, 6.26; 95% confidence interval, 2.

144 ed the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.

145 the malaria positive and EVD positive group (adjusted hazard ratio 9.36, 95% CI 6.18-14.18, p<0.0001)

146 ssociated with cardiovascular events (n=165, adjusted hazard ratio, 9.05 [3.24-25.3], P<0.001) and wi

147 were also associated with ICD-treated VT/VF (adjusted hazard ratio, 9.22; 95% confidence interval, 2.

148 g adherent to all 3 therapies, multivariable-adjusted hazard ratios (95% confidence intervals [CIs])

149 .001) event was significantly lower with Rtx Adjusted hazard ratios (95% confidence intervals) betwee

150 The fully adjusted hazard ratio [95% confidence interval (CI)] for

151 the context of lower sodium (</=138 mmol/L; adjusted hazard ratio [95% confidence interval] for all-

152 er risk of kidney failure and heart failure (adjusted hazard ratio [95% confidence interval] for zero

153 served with a high intake of plant nitrites (adjusted hazard ratio (AHR) = 0.72, 95% confidence inter

154 atin use was not associated with recurrence (adjusted hazard ratio (aHR) = 1.01, 95% confidence inter

155 of age or older (24.2% [95% CI 23.4-24.9%]); Adjusted Hazard Ratio (AHR) = 2.23 (95% CI 2.15-2.31), p

156 lity after adjustment for other factors: the adjusted hazard ratio (aHR) for lower vs middle tertile

157 cted before treatment was associated with an adjusted hazard ratio (aHR) for treatment failure of 20.

158 used Cox regression models to determine the adjusted hazard ratio (aHR) of patient death, death-cens

159 rogression among 6212 women living with HIV (adjusted hazard ratio [aHR] 0.64, 95% CI 0.54-0.75; I(2)

160 Among men, partner's HIV-positive status (adjusted hazard ratio [aHR] 2.67, 1.06-6.82, p=0.040) or

161 = 37/671) compared with quinine (n = 96/945; adjusted hazard ratio [aHR] = 0.73 [95% CI 0.44, 1.21],

162 ) and late (days 101-365) overall mortality (adjusted hazard ratio [aHR] = 1.36, 95% confidence inter

163 hose with PCNSL had increased risk of death (adjusted hazard ratio [aHR] = 11.79) or graft failure/re

164 the first 30 days following IRD acceptance (adjusted hazard ratio [aHR] accept vs decline: 1.22 2.06

165 proficient MMR had significantly better SAR (adjusted hazard ratio [AHR], 0.70; 95% CI, 0.52-0.96; P

166 iate with a higher risk of ESRD in the AASK (adjusted hazard ratio [aHR], 1.19; 95% confidence interv

167 hazard ratio [cHR], 1.59; 95% CI, 1.07-2.36; adjusted hazard ratio [aHR], 1.25; 95% CI, 0.82-1.90) th

168 sociated with a 28% higher risk of dementia (adjusted hazard ratio [aHR], 1.28; 95% CI, 1.13-1.46) ad

169 T >/=30 mmHg included systemic hypertension (adjusted hazard ratio [aHR], 1.29); worse presenting vis

170 ith significantly higher pancreas allograft [adjusted hazard ratio [aHR], 1.37; 95% confidence interv

171 X score, depression was associated with MOF (adjusted hazard ratio [aHR], 1.39; 95% CI, 1.27-1.51; P

172 elevated in persons with moderate fibrosis (adjusted hazard ratio [aHR], 1.42 [95% confidence interv

173 mortality: PSA nadir greater than 0.5 ng/mL (adjusted hazard ratio [aHR], 1.72; 95% CI, 1.17-2.52; P

174 reased for patients with metastatic disease (adjusted hazard ratio [AHR], 2.3; 95% CI, 1.0 to 5.1; P

175 clude age <35 years compared with >35 years (adjusted hazard ratio [aHR], 2.4; 95% CI, 1.5-3.9), curr

176 ong those exposed to thiopurine monotherapy (adjusted hazard ratio [aHR], 2.60; 95% CI, 1.96-3.44; P

177 The month 6 KT ratio (adjusted hazard ratio [aHR], 2.74), soluble CD14 level (

178 d <2 years had an increased hazard of death (adjusted hazard ratio [aHR], 3.13; 95% confidence interv

179 einfection with a heterologous HCV genotype (adjusted Hazard Ratio [aHR]: 0.45, 95% CI: 0.25-0.84) wa

180 ion between CIT and all-cause graft failure (adjusted hazard ratio [aHR]: 1.01, 95% CI: 0.98-1.04, P

181 th higher mortality risk, including overall (adjusted hazard ratio [aHR]: 1.63; 95% confidence interv

182 an independent predictor of total mortality (adjusted hazard ratio [aHR]: 2.31; 95% confidence interv

183 n analysis was used to compute 1- to 35-year adjusted hazard ratios (aHRs) for dementia, controlled f

184 We present incidence rates and adjusted hazard ratios (aHRs).

185 onal hazard models to calculate multivariate-adjusted hazard ratios and 95% confidence intervals (CIs

186 variable Cox regression was used to estimate adjusted hazard ratios and 95% confidence intervals for

187 ds models to estimate age- and multivariable-adjusted hazard ratios and 95% confidence intervals for

188 gression models to estimate the multivariate-adjusted hazard ratios and 95% confidence intervals of i

189 Adjusted hazard ratios and 95% confidence intervals were

190 proportional hazards regression to estimate adjusted hazard ratios and 95% confidence intervals.

191 Age-adjusted hazard ratios comparing black versus white men

192 to 64 years of age in ARIC and REGARDS, age-adjusted hazard ratios comparing blacks versus whites we

193 The adjusted hazard ratio for acute rejection and all-cause

194 schemic, and ischemic patients, respectively-adjusted hazard ratio for Chagasic versus other nonische

195 s/day), time-updated information revealed an adjusted hazard ratio for death of 2.79 (95% confidence

196 The adjusted hazard ratio for diabetes was 3.07 (95% confide

197 received RVD alone (50 months vs. 36 months; adjusted hazard ratio for disease progression or death,

198 In prospective analyses, the multivariable-adjusted hazard ratio for incident diabetes comparing HB

199 An increased ADR was associated with an adjusted hazard ratio for interval colorectal cancer of

200 400 patients within the matched groups, the adjusted hazard ratio for mortality associated with preh

201 The minimally adjusted hazard ratio for mortality risk related to lone

202 Compared with recipients without DGF, the adjusted hazard ratio for overall graft loss at 3 years

203 The adjusted hazard ratio for publication was 1.79 (95% conf

204 The adjusted hazard ratio for SVI was 1.28 (95% confidence i

205 s with those in the lowest, the multivariate-adjusted hazard ratio for T2D was 1.23 (95% confidence i

206 Compared with placebo, the adjusted hazard ratio for the effect of ICD on mortality

207 experienced AKI Network stage 2 or 3 had an adjusted hazard ratio for the primary composite outcome

208 rticipants without acidosis at baseline, the adjusted hazard ratio for those with ammonium excretion

209 ), and matched controls (N = 1,279,754), the adjusted hazard ratios for any liver disease were elevat

210 The adjusted hazard ratios for community-treated infection a

211 ity and heart failure hospitalizations, with adjusted hazard ratios for every 5-bpm increase of 1.14

212 Likewise, the adjusted hazard ratios for hypokalemia and hyperkalemia,

213 gory (such as an ADR > 24.56%) decreased the adjusted hazard ratios for interval colorectal cancer to

214 Survival analysis was used to estimate adjusted hazard ratios for licensing and crash outcomes

215 ecipients who did not experienced DGF-D, the adjusted hazard ratios for overall graft loss and DCGL i

216 Age, sex, and body mass index-adjusted hazard ratios for overall VTE were 0.98 (95% co

217 Adjusted hazard ratios for patients achieving all risk f

218 Adjusted hazard ratios for sudden death in each trial gr

219 Adjusted hazard ratios for suicide attempt and suicide w

220 Fully adjusted hazard ratios for the associations of current s

221 cohort equations), we compared multivariable-adjusted hazard ratios for the composite outcome of inci

222 In random-effects meta-analysis, age-adjusted hazard ratios for the shortest LTL quintile com

223 ity compared with those aged 18 to 24 years (adjusted hazard ratio, for 0-5 years = 0.53, 6-11 = 0.48

224 n D 1alpha-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio >/= 1.47; P for interaction </= 0.

225 invasive breast cancer among those with AF (adjusted hazard ratio (HR) = 1.19, 95% confidence interv

226 d with individuals with normal activity, the adjusted hazard ratio (HR) for cardiovascular events was

227 The age-adjusted hazard ratio (HR) for CRC among female immigran

228 95% confidence interval 13.3-17.7), with an adjusted hazard ratio (HR) of 0.68 (0.52-0.89).

229 diagnosed with atrial fibrillation, with an adjusted hazard ratio (HR) of 1.13 (95% CI 1.01-1.25; p=

230 n non-AF groups (0.97% versus 0.47%) with an adjusted hazard ratio (HR) of 1.64.

231 via excisional biopsy was associated with an adjusted hazard ratio (HR) of 3.0 (95% CI, 2-4.5) and, v

232 iated with death from cancers of the kidney {adjusted hazard ratio (HR) per 4.4 mug/m(3)=1.14 [95% co

233 th individuals without COPD, the age and sex adjusted hazard ratio (HR) was 5.0 (95% CI 2.8-8.9) for

234 For each 10-mug/m(3) increment in PM2.5, adjusted hazard ratio (HR) with 95% confidence interval

235 The multivariate-adjusted hazard ratios (HR) comparing beneficiaries with

236 ultivariate Cox regression analysis to yield adjusted hazard ratios (HR).

237 adverse cardiovascular events (multivariable adjusted hazard ratio [HR(adj)]=0.75, 95% CI 0.66-0.85,

238 .0 months (5.7-8.2) in the ofatumumab group (adjusted hazard ratio [HR] 0.27, 95% CI 0.19-0.39, p<0.0

239 bsolute difference 22.1% [95% CI 11.0-33.3]; adjusted hazard ratio [HR] 0.45 [95% CI 0.33-0.62]; p<0.

240 isk of the composite cardiovascular outcome (adjusted hazard ratio [HR] 1.14, 95% CI 1.03-1.26), card

241 cohorts, non-affective psychotic disorders (adjusted hazard ratio [HR] 1.25, 95% CI 1.09-1.44 in Cam

242 rugs (sDMARDs) had the highest risk of HBVr (adjusted hazard ratio [HR] = 5.14; 95% confidence interv

243 tin users with cirrhosis due to chronic HBV (adjusted hazard ratio [HR], 0.39; 95% confidence interva

244 rs compared with white youths (black youths: adjusted hazard ratio [HR], 0.89; 95% CI, 0.79-0.99; Lat

245 164 patients (37%) in the usual care group (adjusted hazard ratio [HR], 0.98; 95% CI, 0.79-1.22; P =

246 ociation was found between exposure to dogs (adjusted hazard ratio [HR], 1.00; 95% CI, 0.86-1.16) and

247 ed with increased OS when compared with CRT (adjusted hazard ratio [HR], 1.01; 95% CI, 0.74-1.39; P =

248 .01-1.11; P = 0.011), overall graft failure (adjusted hazard ratio [HR], 1.06; 95% CI, 1.02-1.10; P =

249 e likely to require hospitalization overall (adjusted hazard ratio [HR], 1.25; 95% CI, 1.19-1.31) and

250 r doubled levels of creatinine (1985 events; adjusted hazard ratio [HR], 1.26; 95% CI, 1.05-1.51) and

251 select chronic medical conditions (0-1 year adjusted hazard ratio [HR], 4.38 [95% confidence interva

252 a 44% reduction in development of cirrhosis (adjusted hazard ratio [HR]: 0.6; 95% confidence interval

253 d aspirin-treated patients (12.6% vs. 16.0%; adjusted hazard ratio [HR]: 0.83; 95% confidence interva

254 ities had a higher risk of CHD (multivariate-adjusted hazard ratio [HR]: 1.49; 95% confidence interva

255 In cause-specific hazard models, HTN (adjusted hazard ratio [HR]: 1.71; 95% confidence interva

256 calculating minimally adjusted and mutually adjusted hazard ratios [HR] and 95% CIs.

257 ith the ICD versus SPRM quintile 1 patients (adjusted hazard ratios [HR]: 0.602; 95% confidence inter

258 e was no longer a significant OS difference (adjusted hazard ratio [HRadj], 0.92; 95% CI, 0.83 to 1.0

259 ards regression models were used to estimate adjusted hazard ratios (HRs) and 95% CIs after adjusting

260 rtional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% CIs of incident bre

261 ed Cox regression models provided propensity-adjusted hazard ratios (HRs) and 95% confidence interval

262 proportional hazards regression to estimate adjusted hazard ratios (HRs) and 95% confidence interval

263 Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% confidence interval

264 Cox regression yielded adjusted hazard ratios (HRs) associating each disease ou

265 rds regression models, smoking and risk-time adjusted hazard ratios (HRs) between patients and contro

266 ness-death model was applied to estimate the adjusted hazard ratios (HRs) for 3 health transitions (h

267 red with an eGFR of 95 mL/min per 1.73 m(2), adjusted hazard ratios (HRs) for incident study-specific

268 ts without GSD at baseline, the multivariate-adjusted hazard ratios (HRs) for type 2 diabetes for tho

269 person-years were calculated, and crude and adjusted hazard ratios (HRs) were estimated by Cox regre

270 ssion was used to determine propensity score-adjusted hazard ratios (HRs) with 95% confidence interva

271 Cox hazard analysis was used to extract the adjusted hazard ratios (HRs) with adjustments for baseli

272 Results are reported as adjusted hazard ratios (HRs).

273 -3.9 months) in the home oxygen alone group, adjusted hazard ratio of 0.49 (95% CI, 0.31-0.77; P = .0

274 ts (11.5%) in the placebo group, yielding an adjusted hazard ratio of 1.02 (95% CI, 0.87-1.20).

275 ps had a higher risk of perforation, with an adjusted hazard ratio of 1.61 (95% confidence interval [

276 Multivariable regression analysis showed an adjusted hazard ratio of 2.7 (95% CI, 1.5-4.8) for 30-da

277 risk for fatal infection than those without (adjusted hazard ratio of 3.74 (95% CI: 2.57, 5.67)).

278 action, 45+/-6%), RV dysfunction provided an adjusted hazard ratio of 4.2 (P=0.02).

279 Furthermore, L5% significantly increased the adjusted hazard ratio of ischemic lower-extremity PAD (1

280 A multivariable adjusted hazard ratio of mortality for SxOA was 1.98 (95

281 D involvement (27% vs 45%, p<0.001), with an adjusted hazard ratio of not receiving an ID consult of

282 pure ever snus users, and combined users had adjusted hazard ratios of 0.68 (95% confidence interval

283 01) relapses in a dose-response manner, with adjusted hazard ratios of 2.10 (95% CI, 1.45-3.04) and 2

284 not requiring dialysis, was associated with adjusted hazard ratios of 2.60 (95% CI, 1.50-4.51; P = 0

285 The RAS blockade was associated with an adjusted-hazard ratio of 0.63 (95% confidence interval,

286 h an effect-allele-attributed hazards ratio (adjusted hazards ratio) of 1.99 (95% confidence interval

287 ed measurements were taken into account, the adjusted hazard ratio per 1 SD increase of the ST2 level

288 Adjusted hazard ratios per population SD difference (HRs

289 nce x renal replacement therapy interaction (adjusted hazard ratio range, 0.43-0.89; p < 0.001).

290 associated with lower short-term mortality (adjusted hazard ratio range, 0.81; 95% CI, 0.68-0.96) bu

291 , 0.68-0.96) but higher long-term mortality (adjusted hazard ratio range, 1.16-1.22; p = 0.004).

292 ted with higher mortality throughout 1-year (adjusted hazard ratio range, 1.30-1.92; p < 0.001), whic

293 The multivariate-adjusted hazard ratios ranged from 1.78 (95% confidence

294 r risk: Compared with 1-<2 years of use, the adjusted hazard ratio was 0.76 (95% confidence interval:

295 Compared with SOC, the adjusted hazard ratio was 0.98 (95% CI, 0.80 to 1.20; P

296 The adjusted hazard ratios were 1.49 (95% CI, 1.05-2.09) for

297 Adjusted odds ratios and adjusted hazard ratios were estimated by logistic regres

298 Incidence rates were calculated and adjusted hazard ratios were estimated using extended Cox

299 Then, the adjusted hazard ratios were used as weights.

300 rtional hazards models were used to estimate adjusted hazard ratios with 95% CIs of dementia associat

301 We estimated adjusted hazard ratios with time-varying Cox models.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。